Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma

Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara, Mamoru Shiga, Rieko Kondo, Junichi Miyazaki, Masahiro Sugiyama, Yasushi Sasaki, Masahiro Hirose

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Objective: This study evaluated the effects of ebastine on serum eosinophil cationic protein (ECP) levels in patients with bronchial asthma. Patients: Twenty patients with bronchial asthma (11 patients with atopic disease and nine with non-atopic disease) were enrolled in the study. Methods: In an open-label design, all patients received ebastine 10 mg/day for 4 weeks and serum ECP levels, peripheral blood eosinophil counts, morning peak expiratory flow rate (PEFR) and thresholds for airway hyper-responsiveness (D(min) in asthgraphy) were determined before and after treatment. Results: Serum ECP levels and peripheral blood eosinophil counts were significantly decreased. By disease type, no significant change was found in the non atopic patients, while the serum ECP level was significantly (p < 0.001) decreased in the atopic patients. Furthermore, no significant change in D(min) was found but PEFR was significantly (p < 0.019) increased in the atopic type. Conclusion: Ebastine not only inhibits type I allergic reactions, but may also inhibit airway inflammation by reducing serum ECP levels, particularly in patients with atopic bronchial asthma.

Original languageEnglish
Pages (from-to)435-440
Number of pages6
JournalClinical Drug Investigation
Volume17
Issue number6
DOIs
Publication statusPublished - 1999

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma'. Together they form a unique fingerprint.

Cite this